• Please log in or register to access this feature.

Autoimmune, Cholestatic and Biliary Disease

Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis†‡

  1. Amy Dhirapong1,§,
  2. Guo-Xiang Yang1,§,
  3. Steven Nadler2,
  4. Weici Zhang1,
  5. Koichi Tsuneyama1,3,
  6. Patrick Leung1,
  7. Stuart Knechtle4,
  8. Aftab A. Ansari5,
  9. Ross L. Coppel6,
  10. Fu-Tong Liu7,
  11. Xiao-Song He1,
  12. M. Eric Gershwin1,¶,*

Article first published online: 5 FEB 2013

DOI: 10.1002/hep.26067

Issue

Hepatology

Hepatology

Volume 57, Issue 2, pages 708–715, February 2013

Additional Information

How to Cite

Dhirapong, A., Yang, G.-X., Nadler, S., Zhang, W., Tsuneyama, K., Leung, P., Knechtle, S., Ansari, A. A., Coppel, R. L., Liu, F.-T., He, X.-S. and Gershwin, M. E. (2013), Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology, 57: 708–715. doi: 10.1002/hep.26067

Author Information

  1. 1

    Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis, Davis, CA

  2. 2

    Department of Immunology, Bristol-Myers Squibb, Princeton, NJ

  3. 3

    Department of Diagnostic Pathology, Graduate School of Medicine and Pharmaceutical Science for Research, University of Toyama, Toyama, Japan

  4. 4

    Department of Surgery, The Emory Clinic and Hospital, Emory Transplant Center, Atlanta, GA

  5. 5

    Department of Pathology, Emory University School of Medicine, Atlanta, GA

  6. 6

    Department of Microbiology, Monash University, Melbourne, Victoria, Australia

  7. 7

    Department of Dermatology, University of California at Davis, Davis, CA

  1. §

    These authors contributed equally to this work.

  2. fax: 530-752-4669

*Division of Rheumatology, Allergy, and Clinical Immunology, University of California at Davis School of Medicine, 451 Health Sciences Drive, Suite 6510, Davis, CA 95616 fax: 530-752-4669

  1. †

    Potential conflict of interest: Dr. Nadler owns stock in Bristol-Myers Squibb.

  2. ‡

    Financial was support provided by a grant from the National Institutes of Health (DK067003).

  3. §

    These authors contributed equally to this work.

  4. fax: 530-752-4669

Publication History

  1. Issue published online: 5 FEB 2013
  2. Article first published online: 5 FEB 2013
  3. Accepted manuscript online: 19 SEP 2012 11:31AM EST
  4. Manuscript Accepted: 17 AUG 2012
  5. Manuscript Received: 17 JUL 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (773K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (773K)